Unknown PHASE1 INTERVENTIONAL 1-arm NCT04979390

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Tumor

Interventions SHR-1316

Updated 4 times since 2021 Last updated: Jul 16, 2021 Started: Aug 10, 2021 Primary completion: Feb 10, 2022 Completion: Jul 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04979390, this PHASE1 trial focuses on Tumor and remains ongoing. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.